{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:35:30Z","timestamp":1759667730415},"reference-count":46,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1093\/carcin\/bgu013","type":"journal-article","created":{"date-parts":[[2014,1,21]],"date-time":"2014-01-21T03:29:04Z","timestamp":1390274944000},"page":"1132-1143","source":"Crossref","is-referenced-by-count":20,"title":["IRF5 is a target of BCR-ABL kinase activity and reduces CML cell proliferation"],"prefix":"10.1093","volume":"35","author":[{"given":"Michele","family":"Massimino","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Letizia","family":"Consoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Mesuraca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio","family":"Stagno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Tirr\u00f2","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefania","family":"Stella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Stella","family":"Pennisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Romano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro","family":"Buffa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heather M.","family":"Bond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Morrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Sciacca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Di Raimondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Livia","family":"Manzella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Vigneri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2014,1,20]]},"reference":[{"key":"key\n\t\t\t\t20170503055535_CIT0001","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.4049\/jimmunol.176.12.7462","article-title":"Differential activation of IFN regulatory factor (IRF)-3 and IRF-5 transcription factors during viral infection","volume":"176","author":"Cheng","year":"2006","journal-title":"J. Immunol."},{"key":"key\n\t\t\t\t20170503055535_CIT0002","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1006\/scbi.2000.0310","article-title":"The interferon regulatory factors and oncogenesis","volume":"10","author":"Tanaka","year":"2000","journal-title":"Semin. Cancer Biol."},{"key":"key\n\t\t\t\t20170503055535_CIT0003","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/nri1552","article-title":"Roles of interferon-regulatory factors in T-helper-cell differentiation","volume":"5","author":"Lohoff","year":"2005","journal-title":"Nat. Rev. Immunol."},{"key":"key\n\t\t\t\t20170503055535_CIT0004","doi-asserted-by":"crossref","first-page":"23382","DOI":"10.1074\/jbc.M101216200","article-title":"Virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes","volume":"276","author":"Barnes","year":"2001","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170503055535_CIT0005","doi-asserted-by":"crossref","first-page":"e1003118","DOI":"10.1371\/journal.ppat.1003118","article-title":"IRF-3, IRF-5, and IRF-7 coordinately regulate the type I IFN response in myeloid dendritic cells downstream of MAVS signaling","volume":"9","author":"Lazear","year":"(2013)","journal-title":"PLoS Pathog."},{"key":"key\n\t\t\t\t20170503055535_CIT0006","doi-asserted-by":"crossref","first-page":"2556","DOI":"10.1073\/pnas.0712295105","article-title":"A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis","volume":"105","author":"Couzinet","year":"2008","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"key\n\t\t\t\t20170503055535_CIT0007","doi-asserted-by":"crossref","first-page":"2767","DOI":"10.1074\/jbc.M804744200","article-title":"IRF-5 is a mediator of the death receptor-induced apoptotic signaling pathway","volume":"284","author":"Hu","year":"2009","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170503055535_CIT0008","first-page":"6424","article-title":"Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death","volume":"63","author":"Barnes","year":"(2003)","journal-title":"Cancer Res."},{"key":"key\n\t\t\t\t20170503055535_CIT0009","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1158\/1541-7786.MCR-07-0114","article-title":"Interferon regulatory factors IRF5 and IRF7 inhibit growth and induce senescence in immortal Li-Fraumeni fibroblasts","volume":"6","author":"Li","year":"2008","journal-title":"Mol. Cancer Res."},{"key":"key\n\t\t\t\t20170503055535_CIT0010","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1038\/nsmb.1496","article-title":"Insights into interferon regulatory factor activation from the crystal structure of dimeric IRF5","volume":"15","author":"Chen","year":"2008","journal-title":"Nat. Struct. Mol. Biol."},{"key":"key\n\t\t\t\t20170503055535_CIT0011","doi-asserted-by":"crossref","first-page":"e33098","DOI":"10.1371\/journal.pone.0033098","article-title":"Activation of interferon regulatory factor 5 by site specific phosphorylation","volume":"7","author":"Chang Foreman","year":"(2012)","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170503055535_CIT0012","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1074\/jbc.M111.289728","article-title":"IRF-4 suppresses BCR\/ABL transformation of myeloid cells in a DNA binding-independent manner","volume":"287","author":"Jo","year":"2012","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170503055535_CIT0013","doi-asserted-by":"crossref","first-page":"4547","DOI":"10.1182\/blood-2003-01-0291","article-title":"ICSBP\/IRF-8 inhibits mitogenic activity of p210 Bcr\/Abl in differentiating myeloid progenitor cells","volume":"102","author":"Tamura","year":"(2003)","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170503055535_CIT0014","first-page":"132","article-title":"Chronic myeloid leukemia","volume-title":"Hematology\/the Education Program of the American Society of Hematology. Education Program","author":"Melo","year":"(2003)"},{"key":"key\n\t\t\t\t20170503055535_CIT0015","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1038\/nrc1567","article-title":"Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia","volume":"5","author":"Ren","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"key\n\t\t\t\t20170503055535_CIT0016","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1158\/1535-7163.MCT-12-0550","article-title":"Suppression of survivin induced by a BCR-ABL\/JAK2\/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs","volume":"12","author":"Stella","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"key\n\t\t\t\t20170503055535_CIT0017","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/nrm1280","article-title":"Regulation of the c-Abl and Bcr-Abl tyrosine kinases","volume":"5","author":"Hantschel","year":"2004","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"key\n\t\t\t\t20170503055535_CIT0018","doi-asserted-by":"crossref","first-page":"8643","DOI":"10.1038\/sj.onc.1206091","article-title":"Studying the pathogenesis of BCR-ABL+ leukemia in mice","volume":"21","author":"Van Etten","year":"(2002)","journal-title":"Oncogene"},{"key":"key\n\t\t\t\t20170503055535_CIT0019","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1038\/nchembio.775","article-title":"BCR-ABL uncouples canonical JAK2-STAT5 signaling in chronic myeloid leukemia","volume":"8","author":"Hantschel","year":"2012","journal-title":"Nat. Chem. Biol."},{"key":"key\n\t\t\t\t20170503055535_CIT0020","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.1093\/emboj\/16.20.6151","article-title":"Transformation of hematopoietic cells by BCR\/ABL requires activation of a PI-3k\/Akt-dependent pathway","volume":"16","author":"Skorski","year":"1997","journal-title":"EMBO J."},{"key":"key\n\t\t\t\t20170503055535_CIT0021","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O\u2019Hare","year":"(2009)","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20170503055535_CIT0022","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"key\n\t\t\t\t20170503055535_CIT0023","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2003-07-2575","article-title":"Molecular response to imatinib in late chronic-phase chronic myeloid leukemia","volume":"103","author":"Rosti","year":"2004","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170503055535_CIT0024","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/leu.2012.243","article-title":"Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells","volume":"27","author":"Preisinger","year":"(2013)","journal-title":"Leukemia"},{"key":"key\n\t\t\t\t20170503055535_CIT0025","doi-asserted-by":"crossref","first-page":"e17020","DOI":"10.1371\/journal.pone.0017020","article-title":"Interplay between kinase domain autophosphorylation and F-actin binding domain in regulating imatinib sensitivity and nuclear import of BCR-ABL","volume":"6","author":"Preyer","year":"(2011)","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170503055535_CIT0026","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nprot.2009.22","article-title":"Production, concentration and titration of pseudotyped HIV-1-based lentiviral vectors","volume":"4","author":"Kutner","year":"(2009)","journal-title":"Nat. Protoc."},{"key":"key\n\t\t\t\t20170503055535_CIT0027","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/sj.onc.1200885","article-title":"Tyrosine 207 in CRKL is the BCR\/ABL phosphorylation site","volume":"14","author":"de Jong","year":"1997","journal-title":"Oncogene"},{"key":"key\n\t\t\t\t20170503055535_CIT0028","doi-asserted-by":"crossref","first-page":"6082","DOI":"10.1128\/MCB.02202-05","article-title":"Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib","volume":"26","author":"Griswold","year":"2006","journal-title":"Mol. Cell. Biol."},{"key":"key\n\t\t\t\t20170503055535_CIT0029","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1182\/blood-2005-05-2123","article-title":"BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B","volume":"107","author":"Aloisi","year":"(2006)","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170503055535_CIT0030","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/nrm2203","article-title":"Mechanisms of specificity in protein phosphorylation","volume":"8","author":"Ubersax","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"key\n\t\t\t\t20170503055535_CIT0031","doi-asserted-by":"crossref","first-page":"7403","DOI":"10.1158\/0008-5472.CAN-05-0583","article-title":"Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death","volume":"65","author":"Hu","year":"(2005)","journal-title":"Cancer Res."},{"key":"key\n\t\t\t\t20170503055535_CIT0032","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/cncr.22535","article-title":"Imatinib combined with mitoxantrone\/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis","volume":"109","author":"Fruehauf","year":"(2007)","journal-title":"Cancer"},{"key":"key\n\t\t\t\t20170503055535_CIT0033","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1056\/NEJMoa030513","article-title":"Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia","volume":"349","author":"Hughes","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"key\n\t\t\t\t20170503055535_CIT0034","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1200\/JCO.2009.25.5075","article-title":"Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia","volume":"28","author":"Burchert","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"key\n\t\t\t\t20170503055535_CIT0035","doi-asserted-by":"crossref","first-page":"R111","DOI":"10.1186\/bcr3053","article-title":"Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis","volume":"13","author":"Bi","year":"(2011)","journal-title":"Breast Cancer Res."},{"key":"key\n\t\t\t\t20170503055535_CIT0036","doi-asserted-by":"crossref","first-page":"2914","DOI":"10.1038\/sj.onc.1205459","article-title":"Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53","volume":"21","author":"Mori","year":"(2002)","journal-title":"Oncogene"},{"key":"key\n\t\t\t\t20170503055535_CIT0037","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1476-4598-11-21","article-title":"IRF5 promotes the proliferation of human thyroid cancer cells","volume":"11","author":"Massimino","year":"2012","journal-title":"Mol. Cancer"},{"key":"key\n\t\t\t\t20170503055535_CIT0038","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1182\/blood.V97.11.3648","article-title":"Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha","volume":"97","author":"Schmidt","year":"(2001)","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170503055535_CIT0039","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S1535-6108(02)00074-0","article-title":"Critical role for Gab2 in transformation by BCR\/ABL","volume":"1","author":"Sattler","year":"(2002)","journal-title":"Cancer Cell"},{"key":"key\n\t\t\t\t20170503055535_CIT0040","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1182\/blood-2005-08-3087","article-title":"Enhanced sensitivity to inhibition of SHP2, STAT5, and Gab2 expression in chronic myeloid leukemia (CML)","volume":"107","author":"Scherr","year":"(2006)","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170503055535_CIT0041","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0092-8674(00)81348-3","article-title":"Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene","volume":"87","author":"Holtschke","year":"(1996)","journal-title":"Cell"},{"key":"key\n\t\t\t\t20170503055535_CIT0042","doi-asserted-by":"crossref","first-page":"3480","DOI":"10.1182\/blood-2003-08-2970","article-title":"Interferon consensus sequence binding protein (ICSBP; IRF-8) antagonizes BCR\/ABL and down-regulates bcl-2","volume":"103","author":"Burchert","year":"(2004)","journal-title":"Blood"},{"key":"key\n\t\t\t\t20170503055535_CIT0043","first-page":"2549","article-title":"Constitutive activation of SHP2 in mice cooperates with ICSBP deficiency to accelerate progression to acute myeloid leukemia","volume":"284","author":"Konieczna","year":"(2008)","journal-title":"J. Clin. Invest."},{"key":"key\n\t\t\t\t20170503055535_CIT0044","doi-asserted-by":"crossref","first-page":"e42598","DOI":"10.1371\/journal.pone.0042598","article-title":"BRAFV600E negatively regulates the AKT pathway in melanoma cell lines","volume":"7","author":"Chen","year":"(2012)","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t20170503055535_CIT0045","doi-asserted-by":"crossref","first-page":"27354","DOI":"10.1016\/S0021-9258(19)61518-8","article-title":"Negative regulation of the serine\/threonine kinase B-Raf by Akt","volume":"275","author":"Guan","year":"2000","journal-title":"J. Biol. Chem."},{"key":"key\n\t\t\t\t20170503055535_CIT0046","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S1470-2045(10)70209-6","article-title":"KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer","volume":"12","author":"De Roock","year":"(2011)","journal-title":"Lancet Oncol."}],"container-title":["Carcinogenesis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/carcin\/article-pdf\/35\/5\/1132\/14133152\/bgu013.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,24]],"date-time":"2022-03-24T05:56:22Z","timestamp":1648101382000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/carcin\/article-lookup\/doi\/10.1093\/carcin\/bgu013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,20]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2014,1,20]]},"published-print":{"date-parts":[[2014,5]]}},"URL":"https:\/\/doi.org\/10.1093\/carcin\/bgu013","relation":{},"ISSN":["1460-2180","0143-3334"],"issn-type":[{"value":"1460-2180","type":"electronic"},{"value":"0143-3334","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1,20]]}}}